Quality of Life in Asthma and Rhinitis Allergic With Singulair

This study has been completed.

First Received: September 22, 2006 No Changes Posted

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00380705

Purpose

Allow physicians not familiar with anti-leukotriene based therapy to test it

Condition	Intervention	Phase
Asthma Rhinitis Allergic	Drug: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks	Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Quality of Life in Asthma and Rhinitis Allergic With Singulair

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Montelukast sodium Montelukast

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Quality of life measures

Secondary Outcome Measures:

Nocturnal wake up, work or school absences, physical activity and recurrence of asthma and/or rhinitis

Estimated Enrollment:	91
Study Start Date:	March 2005

Eligibility

Ages Eligible for Study:	6 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment
Voluntary acceptance to participate in the study

Exclusion Criteria:

Patients with cystic fibrosis
Patients with known hypersensitivity to singulair or any of its components
Patients with severe chronic asthma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00380705

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Study ID Numbers:	2006_033
Study First Received:	September 22, 2006
Last Updated:	September 22, 2006
ClinicalTrials.gov Identifier:	NCT00380705 History of Changes
Health Authority:	Ecuador: Public Health Ministry

Additional relevant MeSH terms:

Respiratory System Agents
Otorhinolaryngologic Diseases
Bronchial Diseases
Immune System Diseases
Hormone Antagonists
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Asthmatic Agents
Asthma
Rhinitis
Pharmacologic Actions

Nose Diseases
Leukotriene Antagonists
Montelukast
Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Therapeutic Uses
Lung Diseases
Hypersensitivity, Immediate
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on February 08, 2010